You are here: Home: BCU 2|2001: Editor's office

Editor
Neil Love, MD

Associate Editors
Michelle Finkelstein, MD
Richard Kaderman, PhD

Writers
Jennifer Motley, MD
Sally Bogert, RNC, WHCNP

Design
Mark Cantor
Raelene Mercer

Copy Editor
Pat Morrissey/Havlin

Audio Production
Frank Cesarano

Technical Services
Arly Ledezma

Production Coordinator
Cheryl Dominguez

Staff Coordinator
Patricia McWhorter

Web Design
David A. Smith

Contact Information
Neil Love, MD
Director, Physician and Community Education
University of Miami Conference Center
400 SE Second Avenue, Suite 401
Miami, Florida 33131-2117

 

Fax: (305) 377-9998
Email: nlove@med.miami.edu

© NL Communications, Inc. 2001. All rights reserved. This program was supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals LP. The audio tapes, compact discs, Internet content and accompanying printed material is protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or utilizing any information storage and retrieval system, without written permission from the copyright owner. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor. As part of this program, materials and presentations may include information regarding the use of drugs that may be inconsistent with or outside the approved labeling of these products. Healthcare professionals should note that the use of these agents outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. Please refer to the U.S. product information for complete information about each drug.

Table of Contents Top of Page
Table of Contents Top of Page

 

Home · Search

Home

Editor’s Note

Sentinel Node Dissection:
Implications to Medical Oncology


Postmastectomy Radiation
Therapy


Ductal Carcinoma In Situ

ER/PR Results and Endocrine
Therapy


Adjuvant Therapy for Low-risk
Invasive Tumors


ATAC Trial: Arimidex vs
Tamoxifen vs Combination


Bisphosphonates in Primary
Breast Cancer
 

Adjuvant Taxanes: Surgical
Oncology Perspective


Proposed IBIS 2 Prevention Trial:
Arimidex vs Tamoxifen vs Placebo


Predictions of Future Trends
in Breast Cancer Research


Editorial Office

Contact Us

About Us

Terms of use and general disclaimer

 

Home · Contact us
Terms of use and general disclaimer